Teaching Plan | HBS Case Collection | January 2014

MedImmune Ventures

by Richard Hamermesh and Andrew Otazo

Abstract

"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets.

Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; venture capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States;

Citation:

Hamermesh, Richard, and Andrew Otazo. "MedImmune Ventures." Harvard Business School Teaching Plan 814-039, January 2014.